Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H-REPLACE: Rivaroxaban vs Enoxaparin in Acute Coronary Syndrome
NCT03363035Phase 4Completed
- Sponsor
- The Second Xiangya Hospital
- Start
- Jan 2018
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rivaroxaban in acute coronary syndrome (ACS), sponsored by The Second Xiangya Hospital. Started Jan 2018; status: completed.
02
Drugs
rivaroxaban
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT03363035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03363035.